Pursglove Geordan Garrett 4

What Happened
Geordan Garrett Pursglove, CEO, Chairman and Director of Lixte Biotechnology Holdings, received a grant of 350,000 restricted stock units (RSUs) on July 1, 2026. The RSUs were granted under the company’s 2020 Stock Incentive Plan, were awarded at $0.00 per unit (no cash paid), and vested upon satisfaction of the performance conditions in his RSU agreement. The filing reports these as an award/acquisition (transaction code A).

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-02 (timely filing).
• Award: 350,000 RSUs granted at $0.00; reported transaction value $0.
• Shares/units reported after transaction (Column 5): 700,000 RSUs total — consisting of the 350,000 newly awarded RSUs plus 350,000 previously reported RSUs; the filing notes all 700,000 RSUs have vested.
• Footnotes: F1 — each RSU is a contingent right to receive one common share upon vesting (subject to continued service); the 350,000 RSUs vested when performance conditions were met. F2 — Column 5 total includes the new 350,000 RSUs and 350,000 previously outstanding RSUs, all vested.
• No 10b5-1 plan, tax-withholding, or sale reported in this filing.

Context
RSU awards are compensation grants, not open-market purchases or sales. While vested RSUs typically convert to shares (or are settled per the company plan), the Form 4 here reports the grant/vesting event and the RSU counts; it does not show a market purchase or sale of shares. Awards can reflect compensation or performance pay and are not direct indicators of trading sentiment.